Clinical Trial Update: A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash [Phase 2]

View source ↗

Summary

Phase II study evaluating 5% dapsone gel (ACZONE) to treat erlotinib-related rash in patients with non-small cell lung cancer; the trial was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ACZONE (DAPSONE)
• Tarceva (erlotinib)

Snippet

Sponsor: Allergan | Conditions: Rash, Non-small-Cell Lung Cancer | Phase 2 | Status: TERMINATED